ReviewBundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz2025
[Phage therapy in Germany-Update 2025].
Review in Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Isolation, characterization, and therapeutic assessment of novel phage vB_LSKP32 targeting KL64-type carbapenem-resistant Klebsiella pneumoniae.Archives of virology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Phage therapy is a promising approach to combat the antibiotic resistance crisis worldwide and in Germany. However, after widespread use in Germany from the 1930s to the 1960s, the number of patients treated with phages each year dropped to under a hundred in the following decades. An overview of the current situation of phage therapy in Germany and the translational research supporting it is provided. Aspects taken into account here are phage production, phage banks, clinical phage application, and ongoing translational research projects in Germany.There is a lack of phages for clinical use. Phage therapy is only used in a limited number of patients in a few clinics as an individual treatment attempt. There are several phage banks that, due to different institutional backgrounds and guidelines, do not work in a comparable way and only exchange phage stocks in the context of scientific projects. Projects in basic and translational phage research have increased considerably in Germany. The most urgent change seems to be the expansion of phage production capacities.There is still no high-quality evidence on the clinical success of phage therapy in the medical field by means of randomized controlled clinical trials. In close consultation with the regulatory authorities, it seems sensible to urgently enable a few centers to treat patients according to the Belgian model.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.